Anti-EGFR therapy in oesophagogastric cancer: precise but not enough
نویسندگان
چکیده
منابع مشابه
Optimizing Anti-EGFR Therapy in Colorectal Cancer.
Treatment with anti-EGFR monoclonal antibodies has been successfully integrated in the continuum of care for metastatic colorectal cancer. The major challenge is the identification of patients who would benefit from treatment. Currently, the best predictor of efficacy is the absence of mutations in KRAS and NRAS genes. Clin Cancer Res; 21(24); 5415-6. ©2015 AACR.See related article by Peeters e...
متن کاملUnexpected insights for anti-EGFR cancer therapy
Colorectal cancer (CRC) is a major cause of morbidity and mortality. It accounts for over 9% of all malignancies, making it the third most common cancer worldwide and second most common cause of death in the developed world. Treatment of metastatic colorectal cancer (mCRC) is largely palliative, making potentially curative therapy via molecular inhibition of specific cellular targets in CRC a h...
متن کاملClose, but not close enough
The most recent European Society of Cardiology (ESC) guidelines recommend primary percutaneous coronary intervention (PCI) as the preferred treatment for ST-segment elevation myocardial infarction (STEMI) whenever it is available within 90–120 min of the first medical contact [1]. However, timing of symptom onset appears to be hard to adjudicate precisely, and 'ischaemic time' thereby usually e...
متن کاملMechanisms of resistance to anti-EGFR therapy in colorectal cancer
Targeting the epidermal growth factor receptor (EGFR) either alone or in combination with chemotherapy is effective for patients with RAS wild type metastatic colorectal cancer (mCRC). However, only a small percentage of mCRC patients are sensitive to anti-EGFR therapy and even the best cases finally become refractory to this therapy. It has become apparent that the RAS mutations correlate with...
متن کاملOvercoming Resistance to Anti-EGFR Therapy in Colorectal Cancer.
Our understanding of the genetic and nongenetic molecular alterations associated with anti-epidermal growth factor receptor (EGFR) therapy resistance in colorectal cancer (CRC) has markedly expanded in recent years. Mutations in RAS genes (KRAS/NRAS exons 2, 3, or 4) predict a lack of clinical benefit when anti-EGFR monoclonal antibodies (mAbs) are added to chemotherapy. Genetic events in addit...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Annals of Oncology
سال: 2018
ISSN: 0923-7534
DOI: 10.1093/annonc/mdy199